탤페라 (TLPH) 주가

탤페라(TLPH)는 NAS에 상장된 Healthcare · Drug Manufacturers - Specialty & Generic 기업입니다. 현재가 $1.16 (-0.85%), 시가총액 $46.90M, 52주 범위 $0.39 ~ $1.46.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection.

핵심 지표

• 현재가: $1.16 (-0.85%)
• 시가총액: $46.90M
• 52주 최저~최고: $0.39 ~ $1.46
• 섹터: Healthcare
• 산업: Drug Manufacturers - Specialty & Generic
• 거래소: NAS

탤페라의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

탤페라 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (4.5 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 2.73
• 순이익률: 0.00%

자주 묻는 질문